The Risk of Tuberculosis in Korean Patients with Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-alpha Blockers.
10.3346/jkms.2015.30.2.173
- Author:
Ja Min BYUN
1
;
Chang Kyun LEE
;
Sang Youl RHEE
;
Hyo Jong KIM
;
Jung Wook KIM
;
Jae Jun SHIM
;
Jae Young JANG
Author Information
1. Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea. cklee92@paran.com
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Tuberculosis;
Latent Tuberculosis;
Tumor Necrosis Factor-alpha;
Inflammatory Bowel Disease
- MeSH:
6-Mercaptopurine/adverse effects/analogs & derivatives/therapeutic use;
Adult;
Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use;
Antibodies, Monoclonal/adverse effects/therapeutic use;
Cohort Studies;
Colitis, Ulcerative/*drug therapy;
Crohn Disease/*drug therapy;
Female;
Humans;
Latent Tuberculosis/chemically induced/diagnosis/*epidemiology;
Male;
Mycobacterium tuberculosis/isolation & purification;
Republic of Korea;
Retrospective Studies;
Tuberculosis, Pulmonary/chemically induced/diagnosis/*epidemiology;
Tumor Necrosis Factor-alpha/*antagonists & inhibitors
- From:Journal of Korean Medical Science
2015;30(2):173-179
- CountryRepublic of Korea
- Language:English
-
Abstract:
The aims of this study were to assess the risk of tuberculosis (TB) and the status of latent tuberculosis infection (LTBI) in Korean patients with inflammatory bowel disease (IBD) receiving tumor necrosis factor (TNF)-alpha blockers. We reviewed medical records of 525 Korean IBD patients (365 TNF-alpha blocker naive and 160 TNF-alpha blocker exposed) between January 2001 and December 2013. The crude incidence of TB was significantly higher in IBD patients receiving TNF-alpha blockers compared to TNF-alpha-blocker-naive patients (3.1% vs. 0.3%, P=0.011). The mean incidence of TB per 1,000 patient-years was 1.84 for the overall IBD population, 4.89 for TNF-alpha blocker users, and 0.45 for TNF-alpha-blocker-naive patients. The adjusted risk ratio of TB in IBD patients receiving TNF-alpha blocker was 11.7 (95% confidence interval, 1.36-101.3). Pulmonary TB was prevalent in patients treated with TNF-alpha blockers (80.0%, 4/5). LTBI was diagnosed in 17 (10.6%) patients, and none of the 17 LTBI patients experienced reactivation of TB during treatment with TNF-alpha blockers. Treatment with TNF-alpha blockers significantly increased the risk of TB in IBD patients in Korea. De novo pulmonary TB infection was more prevalent than reactivation of LTBI, suggesting an urgent need for specific recommendations regarding TB monitoring during TNF-alpha blocker therapy.
